Vivos Therapeutics, Inc. (VVOS): History, Ownership, Mission, How It Works & Makes Money

Could Vivos Therapeutics, Inc. truly be revolutionizing the approach to sleep apnea treatment? Reporting revenues near $3.9 million for Q3 2024 and having already treated over 40,000 patients cumulatively with its distinctive, non-invasive Vivos System, the company is certainly making waves. It operates within the challenging but vast obstructive sleep apnea market, presenting a unique alternative to traditional therapies. Ready to explore the history, ownership structure, and core business model driving this medical technology innovator forward?

Vivos Therapeutics, Inc. (VVOS) History

Vivos Therapeutics, Inc.'s Founding Timeline

Year established

Vivos Therapeutics, Inc. was incorporated in Colorado in 2016.

Original location

The company initially established its operations in Littleton, Colorado.

Founding team members

R. Kirk Huntsman has been a central figure, serving as Chairman and CEO, guiding the company since its early stages.

Initial capital/funding

While specific seed funding details are not widely publicized, the company initially operated with capital from founders and early investors before pursuing larger private placements and eventually public funding.

Vivos Therapeutics, Inc.'s Evolution Milestones

Vivos Therapeutics, Inc.'s Transformative Moments

The decision to go public in December 2020 was a watershed event. This IPO not only infused the company with necessary expansion capital but also significantly elevated its profile within the medical and investment communities.

Securing successive FDA 510(k) clearances for its therapeutic oral appliances represented critical validation points. These regulatory milestones legitimized the Vivos System for treating mild-to-moderate obstructive sleep apnea and snoring, paving the way for broader adoption by healthcare professionals. Understanding the investment dynamics post-IPO became critical. Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who’s Buying and Why?

Building the Vivos Integrated Provider (VIP) network marked a strategic transformation in its distribution model. Partnering directly with dentists to deliver the Vivos Method allowed the company to scale its reach and integrate its potentially life-changing therapy into established patient care pathways through 2024.

Vivos Therapeutics, Inc. (VVOS) Ownership Structure

Vivos Therapeutics operates as a publicly traded company, meaning its shares are available for purchase by the general public on stock exchanges. This structure results in a diverse ownership base composed primarily of retail investors, company insiders, and institutional holders.

Vivos Therapeutics, Inc.'s Current Status

As of the end of 2024, Vivos Therapeutics, Inc. is listed on the Nasdaq Capital Market under the ticker symbol VVOS. Being a public entity subjects it to regulatory oversight by the Securities and Exchange Commission (SEC), requiring regular financial disclosures and adherence to governance standards.

Vivos Therapeutics, Inc.'s Ownership Breakdown

Understanding who holds the shares provides insight into potential influences on company strategy. For those interested in a deeper dive, consider Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who’s Buying and Why? The ownership distribution as reported for the fiscal year 2024 is approximately as follows:

Vivos Therapeutics, Inc.'s Leadership

The strategic direction and day-to-day operations of the company are guided by its executive team and board of directors. Key figures leading the organization at the close of 2024 included:

• R. Kirk Huntsman: Chairman and Chief Executive Officer
• Bradford D. Peterson: Chief Financial Officer

This leadership team is responsible for executing the company's mission and navigating the complexities of the medical device market, particularly concerning treatments for sleep-disordered breathing.

Vivos Therapeutics, Inc. (VVOS) Mission and Values

Vivos Therapeutics centers its purpose on addressing significant health issues, specifically sleep-disordered breathing, aiming for widespread impact beyond simple financial returns. The company's culture and strategic direction are deeply rooted in this patient-focused objective.

Vivos Therapeutics' Core Purpose

Understanding the driving force behind a company like Vivos provides crucial context for its operations and growth trajectory. It helps stakeholders, including those detailed in Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who’s Buying and Why?, grasp the long-term vision.

Official mission statement

To rid the world of obstructive sleep apnea (OSA).

Vision statement

While not always explicitly stated as a formal vision, Vivos consistently communicates its goal to establish the Vivos Method as a primary treatment option and standard of care for mild-to-moderate OSA and sleep-disordered breathing globally.

Company slogan

The Vivos Method.

Vivos Therapeutics, Inc. (VVOS) How It Works

Vivos Therapeutics develops and commercializes medical technologies aimed at addressing sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA), by focusing on the underlying craniofacial anatomy. The company primarily equips trained dentists and healthcare providers with its proprietary oral appliances and protocols to treat patients.

Vivos Therapeutics, Inc.'s Product/Service Portfolio

Vivos Therapeutics, Inc.'s Operational Framework

Vivos operates primarily through a B2B2C model. It trains independent dentists and, increasingly, medical providers through its Vivos Integrated Practice (VIP) program, equipping them with the knowledge and tools to diagnose and treat SDB using The Vivos System™. Patients are typically identified through screening by these trained providers or direct marketing efforts. Once a patient is deemed a candidate, the provider prescribes the Vivos therapy, takes impressions or scans for custom appliance fabrication (often outsourced), delivers the appliance, and manages the treatment protocol, which usually lasts 12-24 months. Vivos generates revenue mainly from selling the appliances to providers and through fees associated with the VIP program and training. They also offer support services like medical billing assistance to enrolled VIPs, streamlining practice integration. Understanding the financial backing and investor interest is crucial; Exploring Vivos Therapeutics, Inc. (VVOS) Investor Profile: Who’s Buying and Why? offers further insights.

Vivos Therapeutics, Inc.'s Strategic Advantages

• Proprietary Technology: The Vivos System™ represents a unique, patented approach targeting potential anatomical causes of SDB, differentiating it from traditional management therapies like CPAP or mandibular advancement devices.
• Growing Provider Network: The expanding base of trained VIPs creates a distribution network and increases patient access across North America. As of 2024 filings, growing this network remained a key strategic focus.
• Focus on Root Cause: Unlike treatments managing symptoms, Vivos aims for potential lasting resolution by addressing craniofacial development and airway dimensions, a compelling proposition for patients seeking alternatives to lifelong therapy.
• Potential Market Disruption: Successfully treating mild-to-moderate OSA with a non-surgical, non-lifetime intervention could significantly disrupt the large and established sleep apnea market traditionally dominated by CPAP.
• Insurance Reimbursement Pathways: Ongoing efforts and services focused on helping providers navigate medical insurance billing aim to reduce patient out-of-pocket costs and improve treatment accessibility, although reimbursement levels can vary.

Vivos Therapeutics, Inc. (VVOS) How It Makes Money

Vivos Therapeutics generates revenue primarily through the sale of its proprietary Vivos System oral appliances and related services offered to dentists and physicians. The company also earns income from training programs and practice support services for healthcare providers integrating its sleep apnea treatment solution.

Vivos Therapeutics, Inc.'s Revenue Breakdown

Based on financial data leading into the end of fiscal year 2024, the company's revenue streams show a distinct split between tangible products and integrated service offerings.

Vivos Therapeutics, Inc.'s Business Economics

The economics underpinning Vivos Therapeutics hinge on the sale of its medical devices and the value derived from its integrated service model, the Vivos Integrated Practice (VIP) program. Pricing involves the cost of the custom oral appliances, coupled with enrollment fees for dentists participating in the VIP program, which includes training and support. Gross margins on products and services combined hovered around 62% as reported in Q3 2024. However, significant operating expenses, particularly Selling, General & Administrative (SG&A) costs associated with market expansion, sales efforts, and research and development, currently outweigh gross profits, a common scenario for companies investing heavily in growth and market penetration. Managing cash burn remains a key economic focus.

Vivos Therapeutics, Inc.'s Financial Performance

Assessing financial health requires looking beyond just revenue. As of the reporting periods in 2024 (specifically Q3 data), Vivos Therapeutics reported quarterly revenues in the range of $3.4 million, contributing to a Trailing Twelve Month (TTM) revenue figure approaching approximately $14.5 million. While achieving gross profit margins near 62% demonstrates potential unit profitability, the company continued to post significant net losses, around $4.9 million in Q3 2024. Key performance indicators include:

• Revenue growth rate (fluctuating quarterly but showing overall annual increases historically).
• Gross profit margin stability (maintained above 60% recently).
• Operating expense levels relative to revenue.
• Net loss figures and cash flow from operations (consistently negative, requiring financing).

Vivos Therapeutics, Inc. (VVOS) Market Position & Future Outlook

Vivos Therapeutics occupies a specific niche within the large sleep-disordered breathing market, aiming to provide non-invasive oral appliance solutions; its future outlook hinges on broader clinical acceptance, scaling its provider network, and navigating a competitive landscape dominated by established players. Understanding the core objectives driving these efforts is key; explore the Mission Statement, Vision, & Core Values of Vivos Therapeutics, Inc. (VVOS).

Competitive Landscape

The market for sleep apnea treatments is competitive, featuring large, established companies and other specialized providers.

Opportunities & Challenges

Navigating growth requires capitalizing on market trends while mitigating inherent business risks.

Industry Position

As of early 2025, Vivos Therapeutics is positioned as an innovator in the sleep health industry, focusing on its unique oral appliance technology designed to address underlying anatomical issues related to sleep-disordered breathing. While representing a small fraction of the overall market dominated by CPAP devices, its approach offers a distinct alternative for patients seeking non-invasive, potentially long-term solutions. The company's success relies heavily on demonstrating clinical efficacy, gaining broader acceptance within the medical and dental communities, and successfully scaling its unique service delivery model through trained providers. Its standing is that of a niche challenger with disruptive potential, contingent on overcoming significant commercialization and financial hurdles observed through fiscal year 2024.